Portland Maine – Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production.
Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding value and efficiency to custom antibody development with MBS.
A typical recombinant antigen project at MBS will begin with a careful analysis of the protein sequence and characteristics to assess its suitability for bacterial expression. MBS will use this early analysis to anticipate potential risks and guide an expression strategy. After an expression construct has been obtained and the sequence verified, protein production will be evaluated in a small scale trial. Because bacterial recombinant protein expression always possesses the risk of low expression levels or insoluble expression, it is important to have a thorough evaluation process that saves time while also increasing the likelihood of positive outcomes. MBS developed a parallel small scale evaluation method that assesses multiple expression conditions to provide meaningful information regarding expression, isolation, and purification. The result is an efficient early evaluation that produces predictable large scale outcomes thereby supplying ample antigen for antibody development as quickly as possible.
As a company with rich experience in developing custom antibodies to difficult targets, Maine Biotechnology Services brings the specialized perspective of antibody development professionals to recombinant protein development services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. When protein production is complete, MBS provides a seamless transition to immunizations, shortening the overall timeline to obtain antibodies that meet end use requirements.
About Maine Biotechnology Services: Maine Biotechnology Services is a premier provider of antibody services, with a rich core competency in custom hybridoma development, production and characterization. A wide variety of tools and processes have been developed by MBS to refine clone selection early in a project, and to support customers all the way through functional assay preparation. It is the goal of MBS R&D to continuously add quality, synergistic services that create the most convenient and comprehensive antibody development process possible for our customers.
Contact us for a recombinant antigen quote at [email protected] or 207-797-5454